Deutsche Bank AG lowered its stake in shares of Cooper Companies Inc (NYSE:COO) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 276,392 shares of the medical device company’s stock after selling 6,649 shares during the period. Deutsche Bank AG owned 0.56% of Cooper Companies worth $60,214,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently bought and sold shares of the business. BlackRock Inc. lifted its holdings in Cooper Companies by 1.5% during the fourth quarter. BlackRock Inc. now owns 3,616,339 shares of the medical device company’s stock worth $787,926,000 after buying an additional 54,380 shares during the period. Janus Henderson Group PLC lifted its holdings in Cooper Companies by 0.4% during the third quarter. Janus Henderson Group PLC now owns 2,185,268 shares of the medical device company’s stock worth $518,147,000 after buying an additional 9,477 shares during the period. Amundi Pioneer Asset Management Inc. lifted its holdings in Cooper Companies by 10.1% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 1,379,094 shares of the medical device company’s stock worth $300,476,000 after buying an additional 126,156 shares during the period. Westfield Capital Management Co. LP lifted its holdings in Cooper Companies by 47.8% during the third quarter. Westfield Capital Management Co. LP now owns 636,882 shares of the medical device company’s stock worth $151,011,000 after buying an additional 206,003 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Cooper Companies by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 583,128 shares of the medical device company’s stock worth $126,817,000 after buying an additional 17,942 shares during the period. Institutional investors own 98.55% of the company’s stock.
COO has been the subject of a number of analyst reports. Raymond James Financial restated a “buy” rating and set a $265.00 target price on shares of Cooper Companies in a report on Monday, December 4th. Zacks Investment Research upgraded Cooper Companies from a “hold” rating to a “buy” rating and set a $257.00 target price for the company in a report on Tuesday, November 14th. Stifel Nicolaus restated a “buy” rating and set a $265.00 target price (down previously from $275.00) on shares of Cooper Companies in a report on Friday, December 8th. Oppenheimer set a $250.00 target price on Cooper Companies and gave the stock a “hold” rating in a report on Friday, December 8th. Finally, Stephens restated a “hold” rating and set a $270.00 target price on shares of Cooper Companies in a report on Friday, March 9th. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Cooper Companies has a consensus rating of “Hold” and an average target price of $267.50.
Cooper Companies (NYSE:COO) last issued its quarterly earnings data on Thursday, March 8th. The medical device company reported $2.79 EPS for the quarter, beating the consensus estimate of $2.51 by $0.28. Cooper Companies had a return on equity of 16.90% and a net margin of 7.83%. The firm had revenue of $590.00 million during the quarter, compared to analyst estimates of $583.07 million. During the same quarter in the prior year, the business posted $1.93 EPS. The business’s revenue for the quarter was up 18.2% compared to the same quarter last year. sell-side analysts expect that Cooper Companies Inc will post 11.83 earnings per share for the current year.
In other news, Director Gary S. Petersmeyer sold 785 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $229.06, for a total transaction of $179,812.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Allan E. Rubenstein sold 500 shares of the stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $222.00, for a total value of $111,000.00. Following the sale, the director now owns 6,590 shares of the company’s stock, valued at approximately $1,462,980. The disclosure for this sale can be found here. In the last quarter, insiders have sold 104,516 shares of company stock valued at $24,459,155. Company insiders own 1.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/03/14/cooper-companies-inc-coo-shares-sold-by-deutsche-bank-ag.html.
Cooper Companies Company Profile
The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.